生物标志物 生物标志物
Alexander Andrew Wallace1,2, Oliver Zhou1,2, CIndy Marshall3
1Texas A&M College of Medicine, Dallas, TX, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
概括
现实世界的数据表明,与粉样蛋白相关的成像异常 (ARIA) 发生率和特征在阿尔茨海默病 (AD) 患者治疗lecanemab镜像临床试验结果. 这支持lecanemab在常规临床实践中的安全性.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 放射学 放射学是一门学科.
背景情况:
- 与粉样蛋白相关的成像异常 (ARIA),包括脑 (ARIA-E) 和出血 (ARIA-H),是已知的抗粉样蛋白疗法的副作用,如lecanemab.
- 了解lecanemab的现实安全概况对于有关阿尔茨海默病 (AD) 治疗的明智临床决策至关重要.
- 尽管在临床试验中证明了其有效性,但对于lecanemab存在有限的现实世界的安全数据.
研究的目的:
- 在现实临床环境中评估ARIA在接受lecanemab的AD患者中的发生率和特征.
- 将现实世界ARIA数据与CLARITY-AD临床试验的发现进行比较.
- 在接受lecanemab治疗的患者中评估ARIA和APOE基因型之间的关联.
主要方法:
- 对146名阿尔茨海默症患者的回顾性图表审查,这些患者接受了lecanemab治疗.
- 对治疗后的MRI扫描进行分析,以确定ARIA,ARIA-E和ARIA-H.
- 现实世界ARIA数据与CLARITY-AD试验数据的比较,包括APOE基因型分析.
主要成果:
- 现实世界的ARIA发病率和特征与CLARITY-AD试验中观察到的情况非常相似.
- 在现实数据和CLARITY-AD试验之间,在ARIA,ARIA-E,ARIA-H或症状性ARIA发病率方面没有发现统计学上显著的差异.
- 在这个现实世界队列中,APOE基因型没有显示出与ARIA发展或严重性的统计学上显著的关联.
结论:
- 关于ARIA发病率,严重程度和APOE基因型关联的现实数据与CLARITY-AD试验的结果一致.
- 这些发现提供了进一步的证据,支持莱卡涅马布在常规临床实践中的整体安全性.
- 在临床实践中,当遵循适当的使用建议时,可以安全地管理AD的Lecanemab治疗.
相关概念视频
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511